EP0983091A4 - Obesity protein formulations - Google Patents

Obesity protein formulations

Info

Publication number
EP0983091A4
EP0983091A4 EP98902573A EP98902573A EP0983091A4 EP 0983091 A4 EP0983091 A4 EP 0983091A4 EP 98902573 A EP98902573 A EP 98902573A EP 98902573 A EP98902573 A EP 98902573A EP 0983091 A4 EP0983091 A4 EP 0983091A4
Authority
EP
European Patent Office
Prior art keywords
protein formulations
obesity protein
obesity
formulations
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98902573A
Other languages
German (de)
French (fr)
Other versions
EP0983091A1 (en
Inventor
Joseph V Rinella Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP0983091A1 publication Critical patent/EP0983091A1/en
Publication of EP0983091A4 publication Critical patent/EP0983091A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP98902573A 1997-01-17 1998-01-16 Obesity protein formulations Withdrawn EP0983091A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US3571597P 1997-01-17 1997-01-17
US35715P 1997-01-17
US5496997P 1997-08-07 1997-08-07
US6535297P 1997-11-12 1997-11-12
US65352P 1997-11-12
PCT/US1998/000816 WO1998031390A1 (en) 1997-01-17 1998-01-16 Obesity protein formulations
US54969P 2008-05-21

Publications (2)

Publication Number Publication Date
EP0983091A1 EP0983091A1 (en) 2000-03-08
EP0983091A4 true EP0983091A4 (en) 2002-04-10

Family

ID=27364892

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98902573A Withdrawn EP0983091A4 (en) 1997-01-17 1998-01-16 Obesity protein formulations

Country Status (5)

Country Link
EP (1) EP0983091A4 (en)
JP (1) JP2001511180A (en)
AU (1) AU5919998A (en)
CA (1) CA2277282A1 (en)
WO (1) WO1998031390A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031526A1 (en) * 1995-04-06 1996-10-10 Amylin Pharmaceuticals, Inc. Anti-obesity agents
EP0797999A2 (en) * 1996-03-26 1997-10-01 Eli Lilly And Company Formulations of obesity protein
EP0827750A2 (en) * 1996-08-23 1998-03-11 Eli Lilly And Company Obesity protein formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023515A1 (en) * 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
US6165981A (en) * 1995-03-07 2000-12-26 Dade Behring Inc. Stabilizing solutions for proteins and peptides
GB9509164D0 (en) * 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031526A1 (en) * 1995-04-06 1996-10-10 Amylin Pharmaceuticals, Inc. Anti-obesity agents
EP0797999A2 (en) * 1996-03-26 1997-10-01 Eli Lilly And Company Formulations of obesity protein
EP0827750A2 (en) * 1996-08-23 1998-03-11 Eli Lilly And Company Obesity protein formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9831390A1 *

Also Published As

Publication number Publication date
AU5919998A (en) 1998-08-07
CA2277282A1 (en) 1998-07-23
EP0983091A1 (en) 2000-03-08
JP2001511180A (en) 2001-08-07
WO1998031390A1 (en) 1998-07-23

Similar Documents

Publication Publication Date Title
EG23685A (en) Activated protein c formulations
EP1113799A4 (en) Protein formulations
GB9719879D0 (en) Protein
GB9703681D0 (en) Protein complemention
AU1750997A (en) Obesity protein formulations
EP1012262A4 (en) Human frezzled-like protein
EP1151006A4 (en) Human g protein coupled receptor
AU1705197A (en) Obesity protein formulations
GB9715064D0 (en) Protein expression
IL139873A0 (en) Angoistatin-binding protein
GB9700154D0 (en) Peptides
AU2243997A (en) Obesity protein formulations
AU1747297A (en) Obesity protein formulations
ZA984322B (en) Sucrose-binding proteins
GB9720784D0 (en) Protein
GB9828880D0 (en) Protein
AU6569998A (en) Obesity protein formulations
GB9827016D0 (en) Receptor protein
EP0983091A4 (en) Obesity protein formulations
EP0971742A4 (en) Obesity protein formulations
GB9602410D0 (en) Obesity protein formulations
GB9602409D0 (en) Obesity protein formulations
GB9602408D0 (en) Obesity protein formulations
GB9602406D0 (en) Obesity protein formulations
GB9819038D0 (en) Protein

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990715

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020227

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 38/22 A, 7C 07K 14/575 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020517

R18D Application deemed to be withdrawn (corrected)

Effective date: 20020517